TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX)

CUSIP: 89854M101

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class
Equity / Voting Common Stock, par value $0.0001 per share
Shares outstanding
52,382,313
Total 13F shares
31,912,819
Share change
+1,237,449
Total reported value
$186,051,742
Price per share
$5.83
Number of holders
54
Value change
+$7,213,515
Number of buys
33
Number of sells
5

Quarterly Holders Quick Answers

What is CUSIP 89854M101?
CUSIP 89854M101 identifies TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
EcoR1 Capital, LLC
3/4/5 13F
10%+ Owner · Company
9.5%
from 13F
5,000,000
$24,842,500 26 May 2023
Lynx1 Capital Management LP
13F
Company
10%
5,224,600
$13,374,976 30 Sep 2023
13F
Christoph H. Westphal
3/4/5
10%+ Owner
class O/S missing
2,193,472
$10,898,266 20 Jul 2021
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
7.6%
4,000,000
$10,240,000 30 Sep 2023
13F
BVF INC/IL
13F
Company
5.7%
2,989,474
$7,653,053 30 Sep 2023
13F
BAKER BROS. ADVISORS LP
13F
Company
5.3%
2,784,792
$7,129,068 30 Sep 2023
13F
VANGUARD GROUP INC
13F
Company
3.3%
1,752,594
$4,486,641 30 Sep 2023
13F
BlackRock Finance, Inc.
13F
Company
3.2%
1,680,449
$4,301,949 30 Sep 2023
13F
Deer Management Co. LLC
13F
Company
2.4%
1,245,505
$3,188,493 30 Sep 2023
13F
Alphabet Inc.
13F
Company
2.1%
1,077,080
$2,757,324 30 Sep 2023
13F
Simplify Asset Management Inc.
13F
Company
2%
1,046,916
$2,680,105 30 Sep 2023
13F
DC Funds, LP
13F
Company
1.2%
630,000
$1,612,800 30 Sep 2023
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.59%
307,938
$788,582 30 Sep 2023
13F
MORGAN STANLEY
13F
Company
0.5%
259,447
$664,184 30 Sep 2023
13F
Timothy J. Barberich
3/4/5
Director
mixed-class rows
135,286
mixed-class rows
$498,271 18 Dec 2023
STIFEL FINANCIAL CORP
13F
Company
0.22%
116,900
$299,264 30 Sep 2023
13F
NewEdge Wealth, LLC
13F
Company
0.17%
91,463
$234,145 30 Sep 2023
13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC
13F
Company
0.17%
88,300
$226,048 30 Sep 2023
13F
NORTHERN TRUST CORP
13F
Company
0.14%
71,976
$184,259 30 Sep 2023
13F
STATE STREET CORP
13F
Company
0.08%
41,700
$106,752 30 Sep 2023
13F
DC Investments Management, LLC
13F
Company
0.07%
35,563
$91,041 30 Sep 2023
13F
LETKO, BROSSEAU & ASSOCIATES INC
13F
Company
0.06%
32,400
$82,944 30 Sep 2023
13F
AMERICAN CENTURY COMPANIES INC
13F
Company
0.04%
19,212
$49,183 30 Sep 2023
13F
RENAISSANCE TECHNOLOGIES LLC
13F
Company
0.03%
17,700
$45,000 30 Sep 2023
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
0.03%
16,915
$43,302 30 Sep 2023
13F
Pale Fire Capital SE
13F
Company
0.03%
16,575
$42,432 30 Sep 2023
13F
Privium Fund Management (UK) Ltd
13F
Company
0.03%
15,825
$41,462 30 Sep 2023
13F
Aries Wealth Management
13F
Company
0.02%
10,000
$35,300 30 Sep 2023
13F
Waldron Private Wealth LLC
13F
Company
0.02%
10,000
$25,600 30 Sep 2023
13F
Qube Research & Technologies Ltd
13F
Company
0%
2,410
$6,170 30 Sep 2023
13F
UBS Group AG
13F
Company
0%
1,115
$2,854 30 Sep 2023
13F
ATLAS CAPITAL ADVISORS INC.
13F
Company
0%
896
$2,293 30 Sep 2023
13F
WELLS FARGO & COMPANY/MN
13F
Company
0%
286
$732 30 Sep 2023
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
200
$512 30 Sep 2023
13F
Brian M. Silver
3/4/5
Chief Financial Officer
class O/S missing
632,500
13 Jun 2023
Debora Barton
3/4/5
Chief Medical Officer
class O/S missing
430,000
13 Jun 2023
David P. Southwell
3/4/5
Chief Executive Officer, Director
class O/S missing
100,000
02 Feb 2023
William Desmarais
3/4/5
Chief Business Officer
class O/S missing
30,000
25 Jul 2022
Ittai Harel
3/4/5
Director
class O/S missing
9,146
01 Jun 2022

Institutional Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) as of Q4 2023

As of 31 Dec 2023, TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) was held by 54 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 31,912,819 shares. The largest 10 holders included Lynx1 Capital Management LP, EcoR1 Capital, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., BVF INC/IL, BAKER BROS. ADVISORS LP, Propel Bio Management, LLC, VANGUARD GROUP INC, BlackRock Inc., Deer Management Co. LLC, and Alphabet Inc.. This page lists 54 institutional shareholders reporting positions in this security for the Q4 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders
32
Q4 2023 holders
54
Holder diff
22
Investor Q3 2023 Shares Q4 2023 Shares Share Diff Share Chg % Q3 2023 Value $ Q4 2023 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .